Establishment Labs raised its full-year revenue forecast to $269 million to $271 million after second-quarter revenue rose 31.7% year over year to $67.5 million. Adjusted EBITDA improved to positive $3.7 million from a loss of $8.5 million a year earlier. U.S. revenue surged 140.9% to $24.7 million, with more than 100,000 Motiva implants sold and over 2,000 accounts. The Minimally Invasive platform, which includes Mia and Preservé, generated $12.1 million in quarterly revenue, and Preservé exceeded surgeon-training expectations while commanding a significant pricing premium. Gross margin increased to 70.6%, cash reached $71.2 million, and management said no future equity raises are needed, with the company expecting to become free-cash-flow positive in the second half of 2026.
Establishment Labs Holdings IncRaises full-year revenue outlook and reports strong Q2 with improved EBITDA and gross margin.
